Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed this Form 10-K for the fiscal year ended December 31, 2014. The company manufactures packaging components and delivery systems for injectable pharmaceuticals, biologics, medical devices, healthcare, and consumer products. Operations are organized into Packaging Systems and Delivery Systems. International sales represented 54% of consolidated net sales, and approximately 7,000 employees supported global operations.
The filing is an annual report rather than a standalone quarterly filing; fourth-quarter information is included in unaudited quarterly data.
Key Financial Metrics
| ($ in millions, except per-share data) | 2014 | 2013 | Change |
|---|---|---|---|
| Net sales | $1,421.4 | $1,368.4 | +3.9% |
| Gross profit | $447.8 | $434.7 | +3.0% |
| Gross margin | 31.5% | 31.8% | -0.3 points |
| Operating profit | $182.0 | $162.4 | +12.1% |
| Operating margin | 12.8% | 11.9% | +0.9 points |
| Net income | $127.1 | $112.3 | +13.2% |
| Diluted EPS | $1.75 | $1.57 | +11.5% |
| Operating cash flow | $182.9 | $220.5 | -17.1% |
| Capital expenditures | $111.9 | $151.9 | -26.3% |
- Packaging Systems revenue was $1,019.7 million, up 2.4%; operating profit was $223.0 million, up 2.8%.
- Delivery Systems revenue was $402.5 million, up 7.6%; operating profit was $13.5 million, up 43.6%.
- Research and development expense was $37.3 million, compared with $37.9 million in 2013.
- Cash and cash equivalents were $255.3 million; working capital was $406.8 million.
- Total debt declined to $336.7 million from $373.5 million. Net debt-to-total invested capital improved to 7.8% from 13.7%.
- Available borrowing capacity under the revolving credit facility was $266.8 million at year-end, and the company reported compliance with all debt covenants.
- Dividends declared were $0.41 per share, including an increase to $0.11 per share for the fourth quarter. A $100 million share-repurchase authorization was approved, but no shares had been repurchased under the program at year-end.
Material Changes Versus the Prior Comparable Period
- Sales growth was reduced by a $5.5 million unfavorable foreign-currency impact. Excluding currency, sales increased 4.3%.
- Packaging Systems growth reflected higher volumes, pricing, and product mix, but demand for Teflon- and FluroTec-coated components declined because of customer inventory actions related to regulatory issues and formulation changes.
- Delivery Systems benefited from increased contract manufacturing, proprietary reconstitution products, and customer-funded SmartDose clinical development activity. Proprietary products increased to 26.2% of Delivery Systems sales from 24.8%.
- Operating margin expanded primarily because of lower corporate selling, general and administrative costs, including reduced pension and incentive compensation expense, along with improved segment performance.
- Operating cash flow declined by $37.6 million, primarily because 2013 included a $20.0 million nonrefundable SmartDose customer payment and 2014 included a $27.2 million increase in pension contributions.
- Capital spending decreased by $40.0 million as major corporate office and research-building construction was completed in 2013.
- The company repurchased the remaining $0.6 million principal amount of its convertible debentures, effectively completing the debt repurchase program.
- Other comprehensive loss was $86.8 million, driven primarily by foreign-currency translation losses and pension-related items; this reduced accumulated other comprehensive equity to a $119.2 million loss.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expects long-term revenue and margin improvement from demand for higher-quality Packaging Systems products, increased proprietary-product sales in Delivery Systems, capacity expansion, cost savings, emerging-market growth, and continued investment in new products. Management specifically expects currency translation to adversely affect 2015 sales and earnings per share compared with 2014. No specific numerical 2015 earnings or revenue guidance is provided in the filing text.
- Construction of a new Waterford, Ireland facility for insulin-injector cartridges and other high-value packaging components was planned to begin in 2015, subject to approvals.
- Chief Executive Officer and Chairman Donald E. Morel announced plans to retire at the May 2015 annual meeting; a successor search was underway.
- Key risks include foreign-currency volatility, dependence on injectable drug products, pharmaceutical and healthcare customer consolidation, pricing pressure, regulatory approval and product-commercialization delays, manufacturing disruptions, single-source raw materials, commodity costs, product liability, cybersecurity, environmental compliance, and loss of key personnel.
- Daikyo licenses important technologies, including Daikyo CZ, FluroTec, and B2-coating, under agreements expiring in 2017. Management expected renewal, but failure to renew could adversely affect the business.
- The company had $63.0 million of operating lease obligations, $20.4 million of purchase commitments, $80.1 million of future interest obligations, $17.1 million of other long-term liabilities, and $6.9 million of gross unrecognized tax benefits.
- SmartDose contingent consideration was $5.0 million at year-end. Estimated probable payments over the next five years ranged from zero to $4.1 million, while total payments over the product-patent life are uncapped.
- 2014 included a $1.2 million charge for license costs associated with acquired in-process research and $1.8 million of discrete tax charges. No material restructuring or impairment charges were recorded in 2014.
- The Venezuela subsidiary held $2.0 million of net monetary assets denominated in bolivars, including $1.4 million of cash. Loss of access to the official exchange rate or a significant devaluation could require a pre-tax charge of up to the net monetary asset amount.
Important Facts for Investors to Verify
- Whether foreign-exchange headwinds in 2015 offset underlying constant-currency growth and margin gains.
- The sustainability of Delivery Systems’ improved profitability and the timing and commercial adoption of SmartDose, CZ, and other proprietary products.
- The effect of customer inventory normalization and regulatory or formulation changes on high-value Packaging Systems products.
- Debt maturities, particularly the $27.2 million due in 2015 and $76.8 million due in 2016, relative to cash generation and available credit.
- Required pension contributions, the $76.2 million pension underfunding, and sensitivity to discount-rate and asset-return assumptions.
- Renewal terms for Daikyo technology and distribution agreements before their 2017 expiration.
- Progress, approval status, and capital requirements for the planned Ireland facility and other expansion projects.
- Potential exposure from SmartDose contingent consideration, tax uncertainties, Venezuela currency restrictions, raw-material costs, and single-source suppliers.
- The company’s ability to maintain dividends and execute the authorized $100 million repurchase program without reducing investment capacity or liquidity.